The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Open accessAbstract
Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) was highly and universally expressed on myeloma cells while having restricted expression in normal tissues. Elotuzumab (formerly known as HuLuc63), a humanized mAb targeting CS1, is currently in a phase I clinical trial in relapsed/refractory myeloma. In this report we investigated whether the activity of elotuzumab could be enhanced by bortezomib, a reversible proteasome inhibitor with significant activity in myeloma. We first showed that elotuzumab could induce patient-derived myeloma cell killing within the bone marrow microenvironment using a SCID-hu mouse model. We next showed that CS1 gene and cell surface protein expression persisted on myeloma patient-derived plasma cells collected after bortezomib administration. In vitro bortezomib pretreatment of myeloma targets significantly enhanced elotuzumab-mediated antibody-dependent cell-mediated cytotoxicity, both for OPM2 myeloma cells using natural killer or peripheral blood mononuclear cells from healthy donors and for primary myeloma cells using autologous natural killer effector cells. In an OPM2 myeloma xenograft model, elotuzumab in combination with bortezomib exhibited significantly enhanced in vivo antitumor activity. These findings provide the rationale for a clinical trial combining elotuzumab and bortezomib, which will test the hypothesis that combining both drugs would result in enhanced immune lysis of myeloma by elotuzumab and direct targeting of myeloma by bortezomib. [Mol Cancer Ther 2009;8(9):2616–24]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Cited by
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Self-citationLonial, S., Vij, R., Harousseau, J.-L., Facon, T., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X., Tsao, L. C., Westland, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1813 · Cited by 151
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Gomathinayagam, S., Laface, D., Houston-Cummings, N. R., Mangadu, R., Moore, R., Shandil, I., Sharkey, N., Li, H., Stadheim, T. A., & Zha, D. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.05.005 · Cited by 9
Metadata
- Authors
- van Rhee, F., Szmania, S. M., Dillon, M., van Abbema, A. M., Li, X., Stone, M. K., Garg, T. K., Shi, J., Moreno-Bost, A. M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A. G., Zhan, F., Shaughnessy, J. D., Barlogie, B., Yaccoby, S., & Afar, D. E. H.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2009-09-01
- Volume
- 8
- Issue
- 9
- Pages
- 2616-2624
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2172026936
- Cited by
- 176
- References
- 1
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0483
- The paper
- van Rhee, F., Szmania, S. M., Dillon, M., van Abbema, A. M., Li, X., Stone, M. K., Garg, T. K., Shi, J., Moreno-Bost, A. M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A. G., Zhan, F., Shaughnessy, J. D., Barlogie, B., Yaccoby, S., & Afar, D. E. H. (2009). Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0483
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.